Jung D - Search Results

1

Metabolism and excretion of TH-302 in dogs.

Jung D, Jiao H, Duan JX, Matteucci M, Wang R. Jung D, et al. Xenobiotica. 2012 Jul;42(7):687-700. doi: 10.3109/00498254.2011.650234. Epub 2012 Feb 21. Xenobiotica. 2012. PMID: 22352389

2

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. Duan JX, et al. Among authors: jung d. J Med Chem. 2008 Apr 24;51(8):2412-20. doi: 10.1021/jm701028q. Epub 2008 Feb 8. J Med Chem. 2008. PMID: 18257544 Free article.

3

14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M. Duan JX, et al. Among authors: jung b, jung d. J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22. J Med Chem. 2011. PMID: 21341674

4

Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M. Jung D, et al. Cancer Chemother Pharmacol. 2012 Mar;69(3):643-54. doi: 10.1007/s00280-011-1741-6. Epub 2011 Oct 1. Cancer Chemother Pharmacol. 2012. PMID: 21964906

5

Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.

Jung D, Jiao H, Duan JX, Matteucci M, Wang R. Jung D, et al. Xenobiotica. 2012 Apr;42(4):372-88. doi: 10.3109/00498254.2011.622810. Epub 2011 Oct 17. Xenobiotica. 2012. PMID: 22004352

6

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.

Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP. Sun JD, et al. Among authors: jung d. Cancer Biol Ther. 2016 Apr 2;17(4):371-80. doi: 10.1080/15384047.2016.1139268. Epub 2016 Jan 28. Cancer Biol Ther. 2016. PMID: 26818215 Free PMC article. Clinical Trial.

7

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.

Lüpfert C, Dyroff M, von Richter O, Gallemann D, El Bawab S, Dolgos H, Jung D, Hecht S, Johne A. Lüpfert C, et al. Among authors: jung d. CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):829-837. doi: 10.1002/psp4.12360. Epub 2018 Oct 31. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30311747 Free PMC article.

8

Characterization of AST-001 non-clinical pharmacokinetics: A novel selective AKR1C3-activated prodrug in mice, rats, and cynomolgus monkeys.

Meng T, Jung D, Cai XH, Lu ZQ, Yu JB, Qi TY, Meng FY, Ruan MZ, Duan JX. Meng T, et al. Among authors: jung d. Biopharm Drug Dispos. 2024 Apr;45(2):83-92. doi: 10.1002/bdd.2385. Epub 2024 Mar 16. Biopharm Drug Dispos. 2024. PMID: 38492211

9

A Rare Presentation of IgG4-Related Sinusitis With Chronic Nasal Obstruction and Headache: A Case Report and Literature Review.

Jung DW, Choi JY. Jung DW, et al. J Rhinol. 2024 Nov;31(3):179-183. doi: 10.18787/jr.2024.00025. Epub 2024 Nov 30. J Rhinol. 2024. PMID: 39744449 Free PMC article.

10

Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway.

Kim SY, Yoon JH, Jung DH, Kim GH, Kim CH, Lee SK. Kim SY, et al. Among authors: jung dh. Front Immunol. 2024 Dec 16;15:1410904. doi: 10.3389/fimmu.2024.1410904. eCollection 2024. Front Immunol. 2024. PMID: 39737189 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,373 results

Search Page

Filters